BOSTON, MA--(Marketwired - September 03, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the Palace Hotel in New York and at the Aegis Capital Corporation 2014 Healthcare and Technology Conference on Friday, September 12, 2014 at the Wynn Encore in Las Vegas.
The Company's presentation at the Rodman & Renshaw Conference is scheduled to begin at 12:05 PM ET and will be available via a live webcast. To access the webcast, please go to http://wsw.com/webcast/rrshq24/mrna.
There will be an opportunity for investors to meet one-on-one with management at both conferences. Interested investors should contact Ms. Lily Khaykina at email@example.com for the Rodman & Renshaw Conference and Ms. Mally Setton at firstname.lastname@example.org for the Aegis Capital Conference for conference details and admission. To learn more about the Rodman & Renshaw Conference and the Aegis Capital Conference, please visit http://www.rodm.com and http://www.aegiscapcorp.com/wp-content/uploads/2012/05/Vegas-2014-Flyer-12082014.pdf, respectively.
About Marina Biotech, Inc.
Marina Biotech is a leading nucleic acid-based drug discovery and development company focused on rare diseases. Our drug discovery platform, the broadest in the sector, allows us to develop compounds which best counter the underlying pathophysiology associated with a specific rare disease. Using this platform, we are developing proprietary single- and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs and antisense compounds intended to trigger various RNA-based mechanisms of action including RNA interference, microRNA replacement therapy, microRNA inhibition and mRNA translational inhibition, respectively. We believe our chemistry technologies and our comprehensive drug delivery technologies -- which utilize multiple, separate and distinct delivery modalities -- provide us with one of the most unique drug discovery engines for the development of nucleic acid-based therapeutics for rare and orphan diseases. Two of our delivery technologies are currently in human clinical trials, of which one -- SMARTICLES® -- is the only technology delivering both single-stranded and double-stranded nucleic acid payloads. Currently, we are advancing CEQ508, for which we have received FDA orphan drug designation, in a Phase 1 clinical program for patients with Familial Adenomatous Polyposis. In addition, we are expanding our rare disease focus to include myotonic dystrophy and Duchenne's muscular dystrophy. Our goal is to improve human health through the development of nucleic acid-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com.
Marina Biotech Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.